Katie Tryhane
Stock Analyst at Credit Suisse
(2.01)
# 2,413
Out of 4,667 analysts
21
Total ratings
50%
Success rate
3.62%
Average return
Main Sectors:
Stocks Rated by Katie Tryhane
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Initiates: Outperform | $285 | $194.19 | +46.76% | 1 | Aug 25, 2022 | |
| AVTR Avantor | Maintains: Outperform | $47 → $50 | $20.36 | +145.58% | 1 | Sep 10, 2021 | |
| DHR Danaher | Maintains: Outperform | $306 → $370 | $235.05 | +57.41% | 1 | Sep 10, 2021 | |
| SOPH SOPHiA GENETICS | Initiates: Outperform | $22 | $3.13 | +602.88% | 1 | Aug 17, 2021 | |
| IDXX IDEXX Laboratories | Maintains: Outperform | $735 → $770 | $418.55 | +83.97% | 2 | Aug 13, 2021 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Outperform | $44 → $54 | $4.96 | +988.71% | 3 | Aug 11, 2021 | |
| FLGT Fulgent Genetics | Maintains: Underperform | $55 → $65 | $16.95 | +283.48% | 2 | Aug 10, 2021 | |
| ZTS Zoetis | Maintains: Outperform | $206 → $230 | $176.71 | +30.16% | 2 | Aug 9, 2021 | |
| NVST Envista Holdings | Maintains: Outperform | $49 → $55 | $21.39 | +157.13% | 2 | May 6, 2021 | |
| LNTH Lantheus Holdings | Maintains: Neutral | $17 → $20 | $87.32 | -77.10% | 1 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $488 → $490 | $516.10 | -5.06% | 2 | Dec 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $432 → $515 | $228.21 | +125.67% | 2 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $230 → $235 | $212.76 | +10.45% | 1 | Oct 22, 2020 |
Charles River Laboratories International
Aug 25, 2022
Initiates: Outperform
Price Target: $285
Current: $194.19
Upside: +46.76%
Avantor
Sep 10, 2021
Maintains: Outperform
Price Target: $47 → $50
Current: $20.36
Upside: +145.58%
Danaher
Sep 10, 2021
Maintains: Outperform
Price Target: $306 → $370
Current: $235.05
Upside: +57.41%
SOPHiA GENETICS
Aug 17, 2021
Initiates: Outperform
Price Target: $22
Current: $3.13
Upside: +602.88%
IDEXX Laboratories
Aug 13, 2021
Maintains: Outperform
Price Target: $735 → $770
Current: $418.55
Upside: +83.97%
Maravai LifeSciences Holdings
Aug 11, 2021
Maintains: Outperform
Price Target: $44 → $54
Current: $4.96
Upside: +988.71%
Fulgent Genetics
Aug 10, 2021
Maintains: Underperform
Price Target: $55 → $65
Current: $16.95
Upside: +283.48%
Zoetis
Aug 9, 2021
Maintains: Outperform
Price Target: $206 → $230
Current: $176.71
Upside: +30.16%
Envista Holdings
May 6, 2021
Maintains: Outperform
Price Target: $49 → $55
Current: $21.39
Upside: +157.13%
Lantheus Holdings
May 5, 2021
Maintains: Neutral
Price Target: $17 → $20
Current: $87.32
Upside: -77.10%
Dec 2, 2020
Maintains: Neutral
Price Target: $488 → $490
Current: $516.10
Upside: -5.06%
Nov 24, 2020
Maintains: Outperform
Price Target: $432 → $515
Current: $228.21
Upside: +125.67%
Oct 22, 2020
Maintains: Outperform
Price Target: $230 → $235
Current: $212.76
Upside: +10.45%